title: Effect of smoking cessation on lipoprotein A-I and lipoprotein A-I:A-II levels.
abstract: Cigarette smoking is associated with low plasma high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (apo) A-I levels, which may explain, in part, its deleterious effects on coronary heart disease (CHD). In a group of ex-smokers, we assessed the influence of smoking cessation on apo A-I particle levels. Plasma lipid, apolipoprotein, and lipoparticle concentrations of 58 subjects who had completely stopped smoking (ex-smokers) were compared with those of 37 subjects who had continued smoking (smokers) before and after a smoking cessation counseling program. Nutritional intake was recorded before and after the program to adjust for potential interaction with plasma lipid variables. Smokers and ex-smokers were similar in gender distribution, age, body mass index (BMI), social status, and nutrient intake. There were significantly greater increases in total cholesterol (P < .04), HDL-C (P < .005), HDL2-C (P < .008), and lipoprotein (Lp) A-I:A-II (P < .04) in ex-smokers than in smokers. After smoking cessation, ex-smokers consumed more vegetable protein (P < .02) and polysaccharides (P < .04) and had higher plasma levels of HDL-C (P < .0004), apo A-I (P < .001), Lp A-I (P < .007), and Lp A-I:A-II (P < .01) than smokers. Adjustments on nutritional variables did not show any additional difference between ex-smokers and smokers, suggesting that smoking per se effects Lp A-I and Lp A-I:A-II levels. In conclusion, HDL particles including Lp A-I and Lp A-I:A-II are higher in ex-smokers than in smokers.
authors.affiliation: Contrat Jeune Formation Institut National de la Santé et de la Recherche Médicale (INSERM) 95-05, Service d'Etude et de Recherche sur les Lipoprotéines et l'Athérosclérose, Lille, France.
authors.forename: F
authors.initials: F
authors.lastname: Richard
authors.forename: N
authors.initials: N
authors.lastname: Marécaux
authors.forename: J
authors.initials: J
authors.lastname: Dallongeville
authors.forename: M
authors.initials: M
authors.lastname: Devienne
authors.forename: N
authors.initials: N
authors.lastname: Tiem
authors.forename: J C
authors.initials: JC
authors.lastname: Fruchart
authors.forename: M
authors.initials: M
authors.lastname: Fantino
authors.forename: G
authors.initials: G
authors.lastname: Zylberberg
authors.forename: P
authors.initials: P
authors.lastname: Amouyel
mesh_terms: D000328:Adult; D016633:Apolipoprotein A-II / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003376:Counseling; D005260:Female; D006801:Humans; D017270:Lipoprotein(a) / Q000031:analogs & derivatives* / Q000097:blood; D008297:Male; D009747:Nutritional Physiological Phenomena; D012907:Smoking / Q000097:blood*; D016540:Smoking Cessation; D012959:Socioeconomic Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D016633:Apolipoprotein A-II; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D017270:Lipoprotein(a); D014280:Triglycerides; C078260:lipoprotein A-I; D002784:Cholesterol